Skip to main contentAI and Advanced
/
COHANCE · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
CO
NSE · Equity shares · Biotechnology & Drugs30.25 · 6.80%
Cohance Lifesciences COHANCE
NSE:INR 475.2
BSE:INR 439.85
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for COHANCE
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 444.95
Day rangeINR 448.35 — INR 484
52-week rangeINR 266.7 — INR 1,038.9
Volume65.58 L
Market cap16,983.61
P/E64.28
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,268.55
Net Income (INR Cr)179.23
Rev Growth (5 Year %)17.57
EPS Growth (5 Year %)-19.95
P/E Ratio64.28
Book Value66.08
EPS5.24
Price/BV7.19Computed
Research path: Interpret Cohance Lifesciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
COHANCECohance Lifesciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 5,729.64 | 5,480.96 | 2,254.09 |
| Cash Equivalents | 10.52 | 5.83 | 2.25 |
| Other Liabilities Total | 695.93 | 559.21 | 10.5 |
| Long Term Debt | 50.48 | 129.75 | 0 |
| Common Stock Total | 38.26 | 25.46 | 25.46 |
| Other Equity Total | 3,873.03 | 3,623.36 | 0.53 |
| Other Current Assets Total | 217.17 | 209.88 | 1.02 |
| Total Assets | 5,729.64 | 5,480.96 | 2,254.09 |
| Current Portof LT Debt/Capital Leases | 144.44 | 165.06 | 43.76 |
| Cash | 49.14 | 96.65 | 44.98 |
| Total Equity | 3,911.29 | 3,648.82 | 2,050.66 |
| Long Term Investments | 294.67 | 173.93 | 139.95 |
| Total Common Shares Outstanding | 38.26 | 25.46 | 25.46 |
| Property/Plant/Equipment Total-Gross | 173.22 | 331.6 | 1,038.9 |
| Tangible Book Valueper Share Common Eq | 66.08 | 90.49 | 78.12 |
| Goodwill Net | 1,283.65 | 1,238.96 | 60.26 |
| Total Liabilities | 1,818.35 | 1,832.14 | 203.42 |
| Total Debt | 400.49 | 485.93 | 65 |
| Short Term Investments | 268.13 | 203.85 | 776.14 |
| Cashand Short Term Investments | 327.79 | 306.33 | 823.38 |
| Total Receivables Net | 689.07 | 774.59 | 200.79 |
| Deferred Income Tax | 97.9 | 102.59 | 64.79 |
| Accounts Receivable-Trade Net | 681.01 | 772.1 | 134.09 |
| Property/Plant/Equipment Total-Net | 2,163.3 | 2,096.4 | 786.78 |
| Minority Interest | 122.54 | 144.06 | Not available |
| Total Current Liabilities | 645.93 | 705.41 | 106.9 |
| Total Inventory | 562.23 | 467.37 | 233.08 |
| Accounts Payable | 284.58 | 268.43 | 42.36 |
| Other Currentliabilities Total | 216.91 | 271.92 | 20.78 |
| Total Long Term Debt | 256.05 | 320.87 | 21.24 |
| Intangibles Net | 99.52 | 106.35 | 1.67 |
| Other Long Term Assets Total | 51.78 | 53.93 | 2.24 |
| Note Receivable-Long Term | 40.46 | 53.22 | 0.01 |
| Total Current Assets | 1,796.26 | 1,758.17 | 1,263.19 |
| Capital Lease Obligations | 205.57 | 191.12 | 21.24 |
| Accumulated Depreciation Total | Not available | Not available | -252.13 |
| Prepaid Expenses | Not available | Not available | 4.92 |
| Additional Paid-In Capital | Not available | Not available | 109.57 |
| Retained Earnings(Accumulated Deficit) | Not available | Not available | 1,891.39 |
| Notes Payable/Short Term Debt | Not available | Not available | 0 |
| Unrealized Gain(Loss) | Not available | Not available | 23.72 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %22.87
Margins
Operating Margin 12m9.27
Operating Margin 5y Avg26.03
Net Profit Margin 12m6.62
Net Profit Margin 5y20.95
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio7.49
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk54.5
Analyst consensus
ConsensusHold
Consensus score3.25
Analyst opinions8
Strong Sell count2
Sell count2
Hold count1
Buy count2
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 57.49%
- FII
- 6.50%
- MF
- 18.21%
- Other
- 17.80%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Cohance Lifesciences - 10 Nifty 500 stocks plunge over 50% from 52-week highs. Do you own any? - The Economic TimesMarket news · 9 Jul 2026, 1:56 pm
Cohance Lifesciences - 10 Nifty 500 stocks plunge over 50% from 52-week highs. Do you own any? The Economic Times
Cohance Lifesciences (COHANCE) Q2 25/26 earnings summary - QuartrMarket news · 8 Jul 2026, 5:05 am
Cohance Lifesciences (COHANCE) Q2 25/26 earnings summary Quartr
COHANCE LIFESCIENCES LTD Share Price Today - Live COHANCE Stock Price for NSE/BSE - UpstoxMarket news · 3 Jul 2026, 12:30 pm
COHANCE LIFESCIENCES LTD Share Price Today - Live COHANCE Stock Price for NSE/BSE Upstox
Cohance Lifesciences promoter declares no encumbrance on shares - scanx.tradeMarket news · 1 Jul 2026, 6:21 am
Cohance Lifesciences promoter declares no encumbrance on shares scanx.trade
Umang Vohra Appointed Executive Chairman and Group CEO of Cohance Lifesciences - Machine MakerMarket news · 30 Jun 2026, 12:33 am
Umang Vohra Appointed Executive Chairman and Group CEO of Cohance Lifesciences Machine Maker
Cohance seeks govt approval for Umang Vohra as Chairman - scanx.tradeMarket news · 27 Jun 2026, 1:16 am
Cohance seeks govt approval for Umang Vohra as Chairman scanx.trade
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsAudited Results
ShareKeyX Community
Discussion and sentiment for Cohance Lifesciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based company focused on global contract development and manufacturing organization (CDMO) platform. The Company specializes in providing end-to-end solutions across the molecule's lifecycle from early-stage development to large-scale commercialization- with a marquee customer base across pharmaceuticals and specialty chemicals. It offers a platform for the lifecycle of small molecule active pharmaceutical ingredient (API) development and manufacturing. Its Integrated Small Molecule Solutions offers good manufacturing practice (GMP)-grade manufacturing solutions and provides small molecule APIs, advanced intermediates and starting materials. Its APIs commercial product line includes Aripiprazole, Articaine HCl, Atomoxetine HCl, Baclofen, Benserazide, Betahistine DiHCl and others. Its pipeline products include Apixaban, Acotiamide, Dexlansoprazole, Edoxaban, Erdosteine, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- COHANCE
- BSE Code
- 543064
Questions
Stock FAQ
What is the symbol and ISIN of Cohance Lifesciences?
Cohance Lifesciences has the symbol COHANCE and ISIN - INE03QK01018.
What is the current price of Cohance Lifesciences?
Cohance Lifesciences is currently trading at INR 475.20.
What are the year high and year low of Cohance Lifesciences?
Cohance Lifesciences has a year high of INR 1,038.90 and a year low of INR 266.70.
What is the market capitalization of Cohance Lifesciences?
Cohance Lifesciences has a market capitalization of INR 16,983.61 crore.
What is the P/E ratio of Cohance Lifesciences?
Cohance Lifesciences has a P/E ratio of 64.28.
What is the dividend yield of Cohance Lifesciences?
Cohance Lifesciences has a dividend yield of 0.00%.
How is the financial performance of Cohance Lifesciences based on revenue, net income, and EPS?
Cohance Lifesciences has revenue of INR 2,268.55 crore, net income of INR 179.23 crore, and EPS of INR 5.08.
What is the book value of Cohance Lifesciences?
Cohance Lifesciences has a book value of INR 66.08.
What is the debt-to-equity ratio of Cohance Lifesciences?
Cohance Lifesciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Cohance Lifesciences?
Cohance Lifesciences has a price-to-book ratio of 7.19 and a price-to-sales ratio of 7.49.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.